{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T12:11:18Z","timestamp":1790424678432,"version":"4.1.0"},"reference-count":96,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2020,10,5]],"date-time":"2020-10-05T00:00:00Z","timestamp":1601856000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012051","name":"Lupus Research Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012051","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["LR190030"],"award-info":[{"award-number":["LR190030"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R56AR075761"],"award-info":[{"award-number":["R56AR075761"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001582","name":"Dermatology Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001582","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>\n                    Chemokines play important roles in homeostasis and inflammatory processes. While their roles in leukocyte recruitment are well-appreciated, chemokines play additional roles in the body, including mediating or regulating angiogenesis, tumor metastasis and wound healing. In this opinion article, we focus on the role of CXCR3 and its ligands in fibrotic processes. We emphasize differences of the effects of each ligand, CXCL9, CXCL10 and CXCL11, on fibroblasts in different tissues of the body. We include discussions of differences in signaling pathways that may account for protective or pro-fibrotic effects of each ligand in different experimental models and\n                    <ns4:italic>ex vivo<\/ns4:italic>\n                    analysis of human tissues. Our goal is to highlight potential reasons why there are disparate findings in different models, and to suggest ways in which this chemokine axis could be manipulated for the treatment of fibrosis.\n                  <\/ns4:p>","DOI":"10.12688\/f1000research.26728.1","type":"journal-article","created":{"date-parts":[[2020,10,5]],"date-time":"2020-10-05T05:35:39Z","timestamp":1601876139000},"page":"1197","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Potential therapeutic manipulations of the CXCR3 chemokine axis for the treatment of inflammatory fibrosing diseases"],"prefix":"10.12688","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1292-4393","authenticated-orcid":false,"given":"Morgan K.","family":"Groover","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1589-6770","authenticated-orcid":false,"given":"Jillian M.","family":"Richmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2020,10,5]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"106-15","DOI":"10.1038\/nri722","article-title":"Chemokine receptors: multifaceted therapeutic targets.","volume":"2","author":"A Proudfoot","year":"2002","journal-title":"Nat Rev Immunol."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"659-702","DOI":"10.1146\/annurev-immunol-032713-120145","article-title":"Chemokines and chemokine receptors: positioning cells for host defense and immunity.","volume":"32","author":"J Griffith","year":"2014","journal-title":"Annu Rev Immunol."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"597-606","DOI":"10.1038\/nri3049","article-title":"Homeostatic chemokine receptors and organ-specific metastasis.","volume":"11","author":"A Zlotnik","year":"2011","journal-title":"Nat Rev Immunol."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"207-15","DOI":"10.1038\/icb.2010.158","article-title":"CXCR3 ligands: redundant, collaborative and antagonistic functions.","volume":"89","author":"J Groom","year":"2011","journal-title":"Immunol Cell Biol."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"524-9","DOI":"10.1172\/JCI31487","article-title":"Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases.","volume":"117","author":"T Wynn","year":"2007","journal-title":"J Clin Invest."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"5838-49","DOI":"10.1128\/MCB.00556-06","article-title":"CXCR3 requires tyrosine sulfation for ligand binding and a second extracellular loop arginine residue for ligand-induced chemotaxis.","volume":"26","author":"R Colvin","year":"2006","journal-title":"Mol Cell Biol."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"2927-36","DOI":"10.1002\/eji.200324235","article-title":"Molecular characterization of the chemokine receptor CXCR3: evidence for the involvement of distinct extracellular domains in a multi-step model of ligand binding and receptor activation.","volume":"33","author":"G Xanthou","year":"2003","journal-title":"Eur J Immunol."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"9649-54","DOI":"10.1073\/pnas.0904361106","article-title":"Selective engagement of G protein coupled receptor kinases (GRKs) encodes distinct functions of biased ligands.","volume":"106","author":"D Zidar","year":"2009","journal-title":"Proc Natl Acad Sci U S A."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"35039-48","DOI":"10.1074\/jbc.M113.479113","article-title":"Biased agonism as a mechanism for differential signaling by chemokine receptors.","volume":"288","author":"S Rajagopal","year":"2013","journal-title":"J Biol Chem."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"30219-27","DOI":"10.1074\/jbc.M403595200","article-title":"Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function.","volume":"279","author":"R Colvin","year":"2004","journal-title":"J Biol Chem."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"7084-93","DOI":"10.4049\/jimmunol.167.12.7084","article-title":"CXCR3 internalization following T cell-endothelial cell contact: preferential role of IFN-inducible T cell alpha chemoattractant (CXCL11).","volume":"167","author":"A Sauty","year":"2001","journal-title":"J Immunol."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"9547-55","DOI":"10.1074\/jbc.M610931200","article-title":"Inhibition of G alpha i2 activation by G alpha i3 in CXCR3-mediated signaling.","volume":"282","author":"B Thompson","year":"2007","journal-title":"J Biol Chem."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"1959-65","DOI":"10.1182\/blood-2002-12-3945","article-title":"CXCR3-mediated chemotaxis of human T cells is regulated by a Gi- and phospholipase C-dependent pathway and not via activation of MEK\/p44\/p42 MAPK nor Akt\/PI-3 kinase.","volume":"102","author":"M Smit","year":"2003","journal-title":"Blood."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"eaaq1075","DOI":"10.1126\/scisignal.aaq1075","article-title":"Biased agonists of the chemokine receptor CXCR3 differentially control chemotaxis and inflammation.","volume":"11","author":"J Smith","year":"2018","journal-title":"Sci Signal."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"1328-33","DOI":"10.1002\/eji.200323897","article-title":"Chemokines integrate JAK\/STAT and G-protein pathways during chemotaxis and calcium flux responses.","volume":"33","author":"S Soriano","year":"2003","journal-title":"Eur J Immunol."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"2009-22","DOI":"10.1172\/JCI71951","article-title":"CXCL11-dependent induction of FOXP3-negative regulatory T cells suppresses autoimmune encephalomyelitis.","volume":"124","author":"Y Zohar","year":"2014","journal-title":"J Clin Invest."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"617-25","DOI":"10.1161\/01.RES.0000209968.66606.10","article-title":"IP-10 blocks vascular endothelial growth factor-induced endothelial cell motility and tube formation via inhibition of calpain.","volume":"98","author":"R Bodnar","year":"2006","journal-title":"Circ Res."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"981-92","DOI":"10.1084\/jem.184.3.981","article-title":"Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases.","volume":"184","author":"D Arenberg","year":"1996","journal-title":"J Exp Med."},{"key":"ref-19","doi-asserted-by":"crossref","first-page":"1437-43","DOI":"10.4049\/jimmunol.159.3.1437","article-title":"The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis.","volume":"159","author":"M Keane","year":"1997","journal-title":"J Immunol."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"e12700","DOI":"10.1371\/journal.pone.0012700","article-title":"CXCL10 can inhibit endothelial cell proliferation independently of CXCR3.","volume":"5","author":"G Campanella","year":"2010","journal-title":"PLoS One."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"257-65","DOI":"10.1016\/j.yexmp.2016.01.010","article-title":"The CXCL10\/CXCR3 axis promotes cardiac microvascular endothelial cell migration via the p38\/FAK pathway in a proliferation-independent manner.","volume":"100","author":"J Xia","year":"2016","journal-title":"Exp Mol Pathol."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"103-9","DOI":"10.1016\/j.jhep.2013.08.017","article-title":"Post-transplant endothelial progenitor cell mobilization via CXCL10\/CXCR3 signaling promotes liver tumor growth.","volume":"60","author":"C Ling","year":"2014","journal-title":"J Hepatol."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"451-5","DOI":"10.1177\/0271678X15610340","article-title":"What is a pericyte?","volume":"36","author":"D Attwell","year":"2016","journal-title":"J Cereb Blood Flow Metab."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"9945-54","DOI":"10.1074\/jbc.M010303200","article-title":"Signal transduction by the chemokine receptor CXCR3: activation of Ras\/ERK, Src, and phosphatidylinositol 3-kinase\/Akt controls cell migration and proliferation in human vascular pericytes.","volume":"276","author":"A Bonacchi","year":"2001","journal-title":"J Biol Chem."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"3385-91","DOI":"10.3748\/wjg.v11.i22.3385","article-title":"Activation of JAK-STAT pathway is required for platelet-derived growth factor-induced proliferation of pancreatic stellate cells.","volume":"11","author":"A Masamune","year":"2005","journal-title":"World J Gastroenterol."},{"key":"ref-26","doi-asserted-by":"crossref","first-page":"896-901","DOI":"10.3748\/wjg.v12.i6.896","article-title":"Inhibitory effects of interferons on pancreatic stellate cell activation.","volume":"12","author":"J Baumert","year":"2006","journal-title":"World J Gastroenterol."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"216-25","DOI":"10.1038\/jid.2011.245","article-title":"Autocrine regulation of re-epithelialization after wounding by chemokine receptors CCR1, CCR10, CXCR1, CXCR2, and CXCR3.","volume":"132","author":"K Kroeze","year":"2012","journal-title":"J Invest Dermatol."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"34-41","DOI":"10.1111\/j.1524-475X.2008.00439.x","article-title":"Delayed reepithelialization and basement membrane regeneration after wounding in mice lacking CXCR3.","volume":"17","author":"C Yates","year":"2009","journal-title":"Wound Repair Regen."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"244-8","DOI":"10.1089\/wound.2011.0355","article-title":"The Beginning of the End: CXCR3 Signaling in Late-Stage Wound Healing.","volume":"1","author":"A Huen","year":"2012","journal-title":"Adv Wound Care (New Rochelle)."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"484-95","DOI":"10.2353\/ajpath.2007.061092","article-title":"Delayed and deficient dermal maturation in mice lacking the CXCR3 ELR-negative CXC chemokine receptor.","volume":"171","author":"C Yates","year":"2007","journal-title":"Am J Pathol."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"1743-55","DOI":"10.2353\/ajpath.2010.090564","article-title":"Lack of CXC chemokine receptor 3 signaling leads to hypertrophic and hypercellular scarring.","volume":"176","author":"C Yates","year":"2010","journal-title":"Am J Pathol."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"5403-11","DOI":"10.4049\/jimmunol.175.8.5403","article-title":"The chemokines CXCL9, CXCL10, and CXCL11 differentially stimulate G alpha i-independent signaling and actin responses in human intestinal myofibroblasts.","volume":"175","author":"A Kouroumalis","year":"2005","journal-title":"J Immunol."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"17066-74","DOI":"10.1074\/jbc.M212077200","article-title":"CXCR3 and heparin binding sites of the chemokine IP-10 (CXCL10).","volume":"278","author":"G Campanella","year":"2003","journal-title":"J Biol Chem."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"6991-8","DOI":"10.4049\/jimmunol.177.10.6991","article-title":"Oligomerization of CXCL10 is necessary for endothelial cell presentation and in vivo activity.","volume":"177","author":"G Campanella","year":"2006","journal-title":"J Immunol."},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"2648-56","DOI":"10.1182\/blood-2008-04-149039","article-title":"Citrullination of CXCL10 and CXCL11 by peptidylarginine deiminase: a naturally occurring posttranslational modification of chemokines and new dimension of immunoregulation.","volume":"112","author":"T Loos","year":"2008","journal-title":"Blood."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"37-44","DOI":"10.1182\/blood-2006-10-049072","article-title":"Proteolytic processing of CXCL11 by CD13\/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration.","volume":"110","author":"P Proost","year":"2007","journal-title":"Blood."},{"key":"ref-37","doi-asserted-by":"publisher","first-page":"29839-45","DOI":"10.1074\/jbc.M103106200","article-title":"Kinetic investigation of chemokine truncation by CD26\/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family.","volume":"276","author":"A Lambeir","year":"2001","journal-title":"J Biol Chem."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"3554-61","DOI":"10.1182\/blood.v98.13.3554","article-title":"Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties.","volume":"98","author":"P Proost","year":"2001","journal-title":"Blood."},{"key":"ref-39","doi-asserted-by":"publisher","first-page":"21292-304","DOI":"10.1074\/jbc.M115.649855","article-title":"The Positively Charged COOH-terminal Glycosaminoglycan-binding CXCL9(74-103) Peptide Inhibits CXCL8-induced Neutrophil Extravasation and Monosodium Urate Crystal-induced Gout in Mice.","volume":"290","author":"V Vanheule","year":"2015","journal-title":"J Biol Chem."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"530","DOI":"10.3389\/fimmu.2017.00530","article-title":"CXCL9-Derived Peptides Differentially Inhibit Neutrophil Migration In Vivo through Interference with Glycosaminoglycan Interactions.","volume":"8","author":"V Vanheule","year":"2017","journal-title":"Front Immunol."},{"key":"ref-41","first-page":"722-7","article-title":"Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis.","volume":"60","author":"R Pasqualini","year":"2000","journal-title":"Cancer Res."},{"key":"ref-42","doi-asserted-by":"publisher","first-page":"1537-49","DOI":"10.1084\/jem.20021897","article-title":"An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4.","volume":"197","author":"L Lasagni","year":"2003","journal-title":"J Exp Med."},{"key":"ref-43","doi-asserted-by":"publisher","first-page":"6234-40","DOI":"10.4049\/jimmunol.173.10.6234","article-title":"Identification and partial characterization of a variant of human CXCR3 generated by posttranscriptional exon skipping.","volume":"173","author":"J Ehlert","year":"2004","journal-title":"J Immunol."},{"key":"ref-44","doi-asserted-by":"publisher","first-page":"41-9","DOI":"10.1016\/j.cytogfr.2012.08.007","article-title":"Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12.","volume":"24","author":"A Singh","year":"2013","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref-45","doi-asserted-by":"publisher","first-page":"97-102","DOI":"10.1038\/nature12681","article-title":"Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis.","volume":"505","author":"B Ding","year":"2014","journal-title":"Nature."},{"key":"ref-46","doi-asserted-by":"publisher","first-page":"3696-705","DOI":"10.4049\/jimmunol.1101293","article-title":"CXCL9 causes heterologous desensitization of CXCL12-mediated memory T lymphocyte activation.","volume":"190","author":"O Giegold","year":"2013","journal-title":"J Immunol."},{"key":"ref-47","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13075-018-1545-8","article-title":"Antibodies against chemokine receptors CXCR3 and CXCR4 predict progressive deterioration of lung function in patients with systemic sclerosis.","volume":"20","author":"F Weigold","year":"2018","journal-title":"Arthritis Res Ther."},{"key":"ref-48","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3389\/fimmu.2018.00428","article-title":"Autoantibodies in Serum of Systemic Scleroderma Patients: Peptide-Based Epitope Mapping Indicates Increased Binding to Cytoplasmic Domains of CXCR3.","volume":"9","author":"A Recke","year":"2018","journal-title":"Front Immunol."},{"key":"ref-49","doi-asserted-by":"publisher","first-page":"2201-13","DOI":"10.1084\/jem.20052144","article-title":"A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor developmen.","volume":"203","author":"J Burns","year":"2006","journal-title":"J Exp Med."},{"key":"ref-50","doi-asserted-by":"publisher","first-page":"e9175","DOI":"10.1371\/journal.pone.0009175","article-title":"CXCR7 functions as a scavenger for CXCL12 and CXCL11.","volume":"5","author":"U Naumann","year":"2010","journal-title":"PLoS One."},{"key":"ref-51","doi-asserted-by":"publisher","first-page":"2116-24","DOI":"10.1039\/c7mb00247e","article-title":"CXCR7 attenuates the TGF-\u03b2-induced endothelial-to-mesenchymal transition and pulmonary fibrosis.","volume":"13","author":"S Guan","year":"2017","journal-title":"Mol Biosyst."},{"key":"ref-52","doi-asserted-by":"publisher","first-page":"154-62","DOI":"10.1038\/nm.4035","article-title":"Targeting of the pulmonary capillary vascular niche promotes lung alveolar repair and ameliorates fibrosis.","volume":"22","author":"Z Cao","year":"2016","journal-title":"Nat Med."},{"key":"ref-53","doi-asserted-by":"publisher","first-page":"1177-89","DOI":"10.1681\/ASN.2007111179","article-title":"CXCL9, but not CXCL10, promotes CXCR3-dependent immune-mediated kidney disease.","volume":"19","author":"J Menke","year":"2008","journal-title":"J Am Soc Nephrol."},{"key":"ref-54","doi-asserted-by":"publisher","first-page":"78-87","DOI":"10.1016\/j.clim.2013.11.003","article-title":"Protective role of JAK\/STAT signaling against renal fibrosis in mice with unilateral ureteral obstruction.","volume":"150","author":"K Koike","year":"2014","journal-title":"Clin Immunol."},{"key":"ref-55","doi-asserted-by":"publisher","first-page":"1663-70","DOI":"10.1016\/j.jid.2017.04.008","article-title":"Transcriptional and Cytokine Profiles Identify CXCL9 as a Biomarker of Disease Activity in Morphea.","volume":"137","author":"J O\u2019Brien","year":"2017","journal-title":"J Invest Dermatol."},{"key":"ref-56","doi-asserted-by":"publisher","first-page":"R188","DOI":"10.1186\/ar4378","article-title":"Interferon-gamma inducible protein-10 as a potential biomarker in localized scleroderma.","volume":"15","author":"K Magee","year":"2013","journal-title":"Arthritis Res Ther."},{"key":"ref-57","doi-asserted-by":"publisher","first-page":"1212-5","DOI":"10.1016\/j.jid.2017.11.032","article-title":"Regarding \"Transcriptional and Cytokine Profiles Identify CXCL9 as a Biomarker of Disease Activity in Morphea\".","volume":"138","author":"J Mertens","year":"2018","journal-title":"J Invest Dermatol."},{"key":"ref-58","doi-asserted-by":"publisher","first-page":"R18","DOI":"10.1186\/ar3242","article-title":"Dysregulated expression of MIG\/CXCL9, IP-10\/CXCL10 and CXCL16 and their receptors in systemic sclerosis.","volume":"13","author":"B Rabquer","year":"2011","journal-title":"Arthritis Res Ther."},{"key":"ref-59","doi-asserted-by":"publisher","DOI":"10.1101\/19000844","article-title":"An acute bleomycin inflammatory and fibrotic mouse model of morphea is dependent upon CXCL9 and CXCR3.","author":"J Richmond","year":"2019","journal-title":"medRxiv."},{"key":"ref-60","doi-asserted-by":"publisher","first-page":"424-35","DOI":"10.1016\/j.jaut.2010.09.003","article-title":"CXCL10 promotes liver fibrosis by prevention of NK cell mediated hepatic stellate cell inactivation.","volume":"35","author":"E Hintermann","year":"2010","journal-title":"J Autoimmun."},{"key":"ref-61","doi-asserted-by":"publisher","first-page":"382-94","DOI":"10.1016\/j.cyto.2013.05.012","article-title":"Antifibrotic role of chemokine CXCL9 in experimental chronic pancreatitis induced by trinitrobenzene sulfonic acid in rats.","volume":"64","author":"J Shen","year":"2013","journal-title":"Cytokine."},{"key":"ref-62","doi-asserted-by":"publisher","first-page":"724-34","DOI":"10.1038\/labinvest.2012.48","article-title":"The chemokine receptor CXCR3 limits injury after acute toxic liver damage.","volume":"92","author":"M Zaldivar","year":"2012","journal-title":"Lab Invest."},{"key":"ref-63","doi-asserted-by":"publisher","first-page":"1610-9","DOI":"10.1002\/hep.25545","article-title":"Chemokine Cxcl9 attenuates liver fibrosis-associated angiogenesis in mice.","volume":"55","author":"H Sahin","year":"2012","journal-title":"Hepatology."},{"key":"ref-64","doi-asserted-by":"publisher","first-page":"309-19, 319.e1-3","DOI":"10.1053\/j.gastro.2009.03.053","article-title":"Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans.","volume":"137","author":"H Wasmuth","year":"2009","journal-title":"Gastroenterology."},{"key":"ref-65","doi-asserted-by":"publisher","first-page":"395-404","DOI":"10.1165\/rcmb.2004-0175OC","article-title":"Inhibition of pulmonary fibrosis by the chemokine IP-10\/CXCL10.","volume":"31","author":"A Tager","year":"2004","journal-title":"Am J Respir Cell Mol Biol."},{"key":"ref-66","doi-asserted-by":"publisher","first-page":"291-9","DOI":"10.1172\/JCI16861","article-title":"Regulation of pulmonary fibrosis by chemokine receptor CXCR3.","volume":"114","author":"D Jiang","year":"2004","journal-title":"J Clin Invest."},{"key":"ref-67","doi-asserted-by":"publisher","first-page":"2049-57","DOI":"10.1172\/JCI38644","article-title":"Inhibition of pulmonary fibrosis in mice by CXCL10 requires glycosaminoglycan binding and syndecan-4.","volume":"120","author":"D Jiang","year":"2010","journal-title":"J Clin Invest."},{"key":"ref-68","doi-asserted-by":"publisher","first-page":"4989","DOI":"10.3390\/ijms20204989","article-title":"Syndecan-4 Inhibits the Development of Pulmonary Fibrosis by Attenuating TGF-\u03b2 Signaling.","volume":"20","author":"Y Tanino","year":"2019","journal-title":"Int J Mol Sci."},{"key":"ref-69","doi-asserted-by":"publisher","first-page":"217-27","DOI":"10.1093\/cvr\/cvu138","article-title":"CXCR3-independent actions of the CXC chemokine CXCL10 in the infarcted myocardium and in isolated cardiac fibroblasts are mediated through proteoglycans.","volume":"103","author":"A Saxena","year":"2014","journal-title":"Cardiovasc Res."},{"key":"ref-70","doi-asserted-by":"publisher","first-page":"283-90","DOI":"10.1007\/s11010-014-2104-5","article-title":"Crosstalk between TGF-\u03b21 and CXCR3 signaling during urethral fibrosis.","volume":"394","author":"H Xie","year":"2014","journal-title":"Mol Cell Biochem."},{"key":"ref-71","doi-asserted-by":"publisher","first-page":"261-8","DOI":"10.1164\/rccm.200409-1164OC","article-title":"CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling.","volume":"171","author":"M Burdick","year":"2005","journal-title":"Am J Respir Crit Care Med."},{"key":"ref-72","doi-asserted-by":"publisher","first-page":"133-40","DOI":"10.1164\/rccm.200312-1670OC","article-title":"Effects of interferon-gamma 1b on biomarker expression in patients with idiopathic pulmonary fibrosis.","volume":"170","author":"R Strieter","year":"2004","journal-title":"Am J Respir Crit Care Med."},{"key":"ref-73","doi-asserted-by":"publisher","first-page":"1446-1449.e4","DOI":"10.1016\/j.jid.2019.12.019","article-title":"Jak Inhibition Prevents Bleomycin-Induced Fibrosis in Mice and Is Effective in Patients with Morphea.","volume":"140","author":"W Damsky","year":"2020","journal-title":"J Invest Dermatol."},{"key":"ref-74","doi-asserted-by":"publisher","first-page":"3006-15","DOI":"10.1002\/art.34500","article-title":"JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor \u03b2 in systemic sclerosis.","volume":"64","author":"C Dees","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref-75","doi-asserted-by":"publisher","first-page":"40-50","DOI":"10.1177\/2397198319865367","article-title":"The JAK\/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib.","volume":"5","author":"W Wang","year":"2020","journal-title":"J Scleroderma Relat Disord."},{"key":"ref-76","doi-asserted-by":"publisher","first-page":"443-5","DOI":"10.1016\/j.jdcr.2017.12.003","article-title":"Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib.","volume":"4","author":"S Kim","year":"2018","journal-title":"JAAD Case Rep."},{"key":"ref-77","doi-asserted-by":"publisher","first-page":"1467-75","DOI":"10.1136\/annrheumdis-2016-210911","article-title":"JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment.","volume":"76","author":"Y Zhang","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"ref-78","doi-asserted-by":"publisher","first-page":"3212-7","DOI":"10.1158\/1078-0432.CCR-12-0653","article-title":"U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis.","volume":"18","author":"A Deisseroth","year":"2012","journal-title":"Clin Cancer Res."},{"key":"ref-79","doi-asserted-by":"publisher","first-page":"1951-2","DOI":"10.1007\/s00277-014-2096-y","article-title":"Disappearance of fibrosis in secondary myelofibrosis after ruxolitinib treatment: new endpoint to achieve?","volume":"93","author":"M Molica","year":"2014","journal-title":"Ann Hematol."},{"key":"ref-80","doi-asserted-by":"publisher","first-page":"1188-91","DOI":"10.4065\/mcp.2011.0518","article-title":"Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis.","volume":"86","author":"A Tefferi","year":"2011","journal-title":"Mayo Clin Proc."},{"key":"ref-81","doi-asserted-by":"publisher","first-page":"833-8","DOI":"10.1002\/ajh.24775","article-title":"A life-threatening ruxolitinib discontinuation syndrome.","volume":"92","author":"G Coltro","year":"2017","journal-title":"Am J Hematol."},{"key":"ref-82","doi-asserted-by":"publisher","first-page":"eaat3834","DOI":"10.1126\/sciadv.aat3834","article-title":"Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis.","volume":"4","author":"D Tvorogov","year":"2018","journal-title":"Sci Adv."},{"key":"ref-83","doi-asserted-by":"publisher","first-page":"697-704","DOI":"10.1007\/s40265-017-0723-3","article-title":"Baricitinib: First Global Approval.","volume":"77","author":"A Markham","year":"2017","journal-title":"Drugs."},{"key":"ref-84","doi-asserted-by":"publisher","first-page":"120-8","DOI":"10.1056\/NEJMoa2015432","article-title":"Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19.","volume":"383","author":"M Ackermann","year":"2020","journal-title":"N Engl J Med."},{"key":"ref-85","doi-asserted-by":"publisher","first-page":"4185-97","DOI":"10.1074\/jbc.M116.745877","article-title":"Antibody Neutralization of CXCL10 in Vivo Is Dependent on Binding to Free and Not Endothelial-bound Chemokine: IMPLICATIONS FOR THE DESIGN OF A NEW GENERATION OF ANTI-CHEMOKINE THERAPEUTIC ANTIBODIES.","volume":"292","author":"P Bonvin","year":"2017","journal-title":"J Biol Chem."},{"key":"ref-86","doi-asserted-by":"publisher","first-page":"259-60","DOI":"10.1038\/nrd3980","article-title":"Antibody-drug conjugates.","volume":"12","author":"R Zolot","year":"2013","journal-title":"Nat Rev Drug Discov."},{"key":"ref-87","doi-asserted-by":"publisher","first-page":"4361-74","DOI":"10.1039\/c8cs00676h","article-title":"Cleavable linkers in antibody-drug conjugates.","volume":"48","author":"J Bargh","year":"2019","journal-title":"Chem Soc Rev."},{"key":"ref-88","doi-asserted-by":"publisher","first-page":"16014","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumours.","volume":"1","author":"S Wilhelm","year":"2016","journal-title":"Nat Rev Mater."},{"key":"ref-89","doi-asserted-by":"publisher","first-page":"585-608","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline.","volume":"18","author":"A Labrijn","year":"2019","journal-title":"Nat Rev Drug Discov."},{"key":"ref-90","doi-asserted-by":"publisher","first-page":"470-91","DOI":"10.1016\/j.addr.2011.01.012","article-title":"Nanoparticles and microparticles for skin drug delivery.","volume":"63","author":"T Prow","year":"2011","journal-title":"Adv Drug Deliv Rev."},{"key":"ref-91","doi-asserted-by":"publisher","first-page":"581-7","DOI":"10.1016\/j.addr.2003.10.023","article-title":"Microneedles for transdermal drug delivery.","volume":"56","author":"M Prausnitz","year":"2004","journal-title":"Adv Drug Deliv Rev."},{"key":"ref-92","doi-asserted-by":"publisher","first-page":"e0119360","DOI":"10.1371\/journal.pone.0119360","article-title":"A DPP-4 inhibitor suppresses fibrosis and inflammation on experimental autoimmune myocarditis in mice.","volume":"10","author":"H Hirakawa","year":"2015","journal-title":"PLoS One."},{"key":"ref-93","doi-asserted-by":"publisher","first-page":"2120-31","DOI":"10.2337\/db13-1029","article-title":"Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen.","volume":"63","author":"K Kanasaki","year":"2014","journal-title":"Diabetes."},{"key":"ref-94","doi-asserted-by":"publisher","first-page":"106774","DOI":"10.1016\/j.intimp.2020.106774","article-title":"Vildagliptin, a CD26\/DPP4 inhibitor, ameliorates bleomycin-induced pulmonary fibrosis via regulating the extracellular matrix.","volume":"87","author":"Y Liu","year":"2020","journal-title":"Int Immunopharmacol."},{"key":"ref-95","doi-asserted-by":"publisher","first-page":"1-11","DOI":"10.1016\/j.lfs.2008.10.001","article-title":"Modulation of cytokine production and silica-induced lung fibrosis by inhibitors of aminopeptidase N and of dipeptidyl peptidase-IV-related proteases.","volume":"84","author":"U K\u00fchlmann","year":"2009","journal-title":"Life Sci."},{"key":"ref-96","doi-asserted-by":"publisher","first-page":"1028-40","DOI":"10.1038\/nm.2807","article-title":"Mechanisms of fibrosis: therapeutic translation for fibrotic disease.","volume":"18","author":"T Wynn","year":"2012","journal-title":"Nat Med."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/9-1197\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/9-1197\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/9-1197\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,8]],"date-time":"2023-10-08T21:15:16Z","timestamp":1696799716000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/9-1197\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,5]]},"references-count":96,"URL":"https:\/\/doi.org\/10.12688\/f1000research.26728.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.29512.r72473","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.29512.r72472","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.29512.r72472","asserted-by":"object"},{"id-type":"doi","id":"10.5256\/f1000research.29512.r72473","asserted-by":"object"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,5]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/9-1197\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.29512.r72473, Christian D. Sadik, Department of Dermatology, Allergy, and Venereology, University of L\u00fcbeck, L\u00fcbeck, Germany, 16 Oct 2020, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/9-1197\/v1#referee-response-72473","order":0,"name":"referee-response-72473","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"<b>Jillian Richmond<\/b>; <i>Posted: 19 Oct 2020<\/i>; We thank Dr. Sadik for taking the time to review our opinion article.","URL":"https:\/\/f1000research.com\/articles\/9-1197\/v1#referee-comment-6051","order":1,"name":"referee-comment-6051","label":"Referee Comment","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.29512.r72472, Patricia A. Pioli, Department of Microbiology and Immunology, Geisel School of Medicine, Lebanon, NH, USA, 22 Oct 2020, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/9-1197\/v1#referee-response-72472","order":2,"name":"referee-response-72472","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"<b>Jillian Richmond<\/b>; <i>Posted: 22 Oct 2020<\/i>; We thank Dr. Pioli for taking the time to review our opinion article. We agree that future studies\/reviews could focus on targeting specific immune cell populations in the context of different fibrosing disorders.","URL":"https:\/\/f1000research.com\/articles\/9-1197\/v1#referee-comment-6057","order":3,"name":"referee-comment-6057","label":"Referee Comment","group":{"name":"article-reports","label":"Article Reports"}},{"value":"JMR is supported by the National Institutes of Health [R56AR075761], a Career Development Award from the Dermatology Foundation, a Target Identification in Lupus Award from the Lupus Research Alliance and a Concept Award from the US Department of Defense Lupus Research Program [#LR190030]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":4,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}